125 related articles for article (PubMed ID: 37742107)
1. Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways.
Xiao X; Chen M; Sang Y; Xue J; Jiang K; Chen Y; Zhang L; Yu S; Lv W; Li Y; Liu R; Xiao H
Thyroid; 2023 Dec; 33(12):1441-1454. PubMed ID: 37742107
[No Abstract] [Full Text] [Related]
2. TBX1 Functions as a Tumor Suppressor in Thyroid Cancer Through Inhibiting the Activities of the PI3K/AKT and MAPK/ERK Pathways.
Wang N; Li Y; Wei J; Pu J; Liu R; Yang Q; Guan H; Shi B; Hou P; Ji M
Thyroid; 2019 Mar; 29(3):378-394. PubMed ID: 30543152
[TBL] [Abstract][Full Text] [Related]
3. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
4. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K/AKT pathway in papillary thyroid carcinoma.
Zheng T; Zhou Y; Xu X; Qi X; Liu J; Pu Y; Zhang S; Gao X; Luo X; Li M; Wang X; Dong L; Wang Y; Mao C
J Transl Med; 2022 Jan; 20(1):20. PubMed ID: 34991623
[TBL] [Abstract][Full Text] [Related]
5. Transcription factor ATF3 mediates the radioresistance of breast cancer.
Zhao W; Sun M; Li S; Chen Z; Geng D
J Cell Mol Med; 2018 Oct; 22(10):4664-4675. PubMed ID: 30117642
[TBL] [Abstract][Full Text] [Related]
6. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.
Fu J; Lv H; Guan H; Ma X; Ji M; He N; Shi B; Hou P
BMC Cancer; 2013 Oct; 13():462. PubMed ID: 24098937
[TBL] [Abstract][Full Text] [Related]
9. CircNDST1 promotes papillary thyroid cancer progression via its interaction with CSNK2A1 to activate the PI3K-Akt pathway and epithelial-mesenchymal transition.
Shu C; Wang S; Hu J; Xu M; Deng H; Maimaiti Y; Huang T
J Endocrinol Invest; 2023 Mar; 46(3):545-557. PubMed ID: 36306106
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation-mediated silencing of Neuronatin promotes hepatocellular carcinoma proliferation through the PI3K-Akt signaling pathway.
Deng Y; Lu L; Liang X; Li J; Zhu D; Huang H; Zhang Y; Zhang X; Chen Y; Liu X; Fu Y
Life Sci; 2023 Jan; 312():121266. PubMed ID: 36473542
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W
Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586
[TBL] [Abstract][Full Text] [Related]
12. ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression.
Chen C; Ge C; Liu Z; Li L; Zhao F; Tian H; Chen T; Li H; Yao M; Li J
J Exp Clin Cancer Res; 2018 Oct; 37(1):263. PubMed ID: 30376856
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Xing M
Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
[TBL] [Abstract][Full Text] [Related]
14. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
15. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
18. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
Wu YC; Li SY; Jia YF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
